F-STAR THERAPEUTICS INC (FSTX) Stock Price, Quote, News and Overview
NASDAQ:FSTX - Nasdaq - US30315R1077 - Common Stock - Currency: USD
FSTX Quote, Performance and Key Statistics
7.12
0 (0%)
The current stock price of FSTX is 7.12 USD. In the past month the price increased by 58.22%. In the past year, price increased by 138.13%.
FSTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.05 | 327.98B | ||
| AMGN | AMGEN INC | 13.23 | 147.69B | ||
| GILD | GILEAD SCIENCES INC | 13.61 | 131.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.41 | 64.18B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.88B | ||
| ARGX | ARGENX SE - ADR | 97.85 | 35.07B | ||
| ONC | BEIGENE LTD-ADR | 5.77 | 25.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.43B | ||
| NTRA | NATERA INC | N/A | 20.78B | ||
| BIIB | BIOGEN INC | 8.12 | 18.82B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.62B |
Related stock screener links
About FSTX
Company Profile
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. The firm's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. The company is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.
Company Info
F-STAR THERAPEUTICS INC
Eddeva B920, Babraham Research Campus
CAMBRIDGE MASSACHUSETTS CB22 3AT GB
CEO: Eliot Forster
Employees: 84
Phone: 441223497400.0
F-STAR THERAPEUTICS INC / FSTX FAQ
What is the stock price of F-STAR THERAPEUTICS INC today?
The current stock price of FSTX is 7.12 USD.
What is the ticker symbol for F-STAR THERAPEUTICS INC stock?
The exchange symbol of F-STAR THERAPEUTICS INC is FSTX and it is listed on the Nasdaq exchange.
On which exchange is FSTX stock listed?
FSTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for F-STAR THERAPEUTICS INC stock?
9 analysts have analysed FSTX and the average price target is 7.14 USD. This implies a price increase of 0.28% is expected in the next year compared to the current price of 7.12. Check the F-STAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is F-STAR THERAPEUTICS INC worth?
F-STAR THERAPEUTICS INC (FSTX) has a market capitalization of 156.51M USD. This makes FSTX a Micro Cap stock.
How many employees does F-STAR THERAPEUTICS INC have?
F-STAR THERAPEUTICS INC (FSTX) currently has 84 employees.
What are the support and resistance levels for F-STAR THERAPEUTICS INC (FSTX) stock?
F-STAR THERAPEUTICS INC (FSTX) has a support level at 5.09. Check the full technical report for a detailed analysis of FSTX support and resistance levels.
Is F-STAR THERAPEUTICS INC (FSTX) expected to grow?
The Revenue of F-STAR THERAPEUTICS INC (FSTX) is expected to decline by -70.62% in the next year. Check the estimates tab for more information on the FSTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy F-STAR THERAPEUTICS INC (FSTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FSTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FSTX, evaluating the profitability, health, valuation and growth aspects
- F-STAR THERAPEUTICS INC (FSTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- F-STAR THERAPEUTICS INC (FSTX) Sales and EPS estimates to see what analysts future expectations are.
- F-STAR THERAPEUTICS INC (FSTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- F-STAR THERAPEUTICS INC (FSTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- F-STAR THERAPEUTICS INC (FSTX) Stock Chart to make your own analysis
- F-STAR THERAPEUTICS INC (FSTX) Latest news and press-releases to stay up to date.
Does F-STAR THERAPEUTICS INC (FSTX) stock pay dividends?
FSTX does not pay a dividend.
When does F-STAR THERAPEUTICS INC (FSTX) report earnings?
F-STAR THERAPEUTICS INC (FSTX) will report earnings on 2023-05-08.
What is the Price/Earnings (PE) ratio of F-STAR THERAPEUTICS INC (FSTX)?
F-STAR THERAPEUTICS INC (FSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
FSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FSTX. When comparing the yearly performance of all stocks, FSTX is one of the better performing stocks in the market, outperforming 98.78% of all stocks.
FSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FSTX. The financial health of FSTX is average, but there are quite some concerns on its profitability.
FSTX Financial Highlights
Over the last trailing twelve months FSTX reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 60.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.15 |
FSTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to FSTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -39.55% and a revenue growth -70.62% for FSTX